OBJECTIVE: To evaluate the efficacy of oral cyclosporine A (CyA) in the treatment of refractory interstitial cystitis-bladder pain syndrome (IC-BPS) and to assess safety using drug level and renal function monitoring. MATERIALS AND METHODS:Patients with IC-BPS who failed at least 2 prior treatments were enrolled in an open-label study oforal CyA. Medication was started at 3 mg/kg divided twice daily for 3 months. Dose was adjusted based on side effects and the drug level was measured 2 hours after the morning dose (C2). The primary end point was moderate or marked improvement of global response assessment or >50% improvement on the Interstitial Cystitis Symptom Index (ICSI) or Interstitial Cystitis Problem Index at 3 months. RESULTS:Twenty-two of 26 patients completed the 3-month follow-up; 18 completed the poststudy evaluation. The median symptom duration was 66 months (12-336). At 3 months, 31% (8/26) improved by global response assessment, 15% (4/26) had >50% improvement in the ICSI score, and 19% (5/26) had an improvement in the Interstitial Cystitis Problem Index score. Hunner lesions (HLs) predicted an improvement in the ICSI score (odds ratio = 15.4, 95% confidence interval: 1.7-224.6, P = .01), with 75% (3/4) of the responders having HL. Two patients withdrew because of hypertension or elevated serum glucose. The mean nuclear glomerular filtration rate declined at 3 months (98.9 ± 31.6 vs 84.2 ± 25.5 mL/min/1.73 m2, P = .01) and reversed to baseline after discontinuation of treatment. C2 levels did not correlate with symptoms but allowed dose reduction in 11 patients. CONCLUSION: Per American Urological Association guidelines, CyA can be effective in a proportion of patients with refractory IC-BPS. Patients with HL are more likely to benefit. Monitoring of C2 rather than trough levels can lead to dose reduction, thereby minimizing toxicity.
RCT Entities:
OBJECTIVE: To evaluate the efficacy of oral cyclosporine A (CyA) in the treatment of refractory interstitial cystitis-bladder pain syndrome (IC-BPS) and to assess safety using drug level and renal function monitoring. MATERIALS AND METHODS:Patients with IC-BPS who failed at least 2 prior treatments were enrolled in an open-label study of oral CyA. Medication was started at 3 mg/kg divided twice daily for 3 months. Dose was adjusted based on side effects and the drug level was measured 2 hours after the morning dose (C2). The primary end point was moderate or marked improvement of global response assessment or >50% improvement on the Interstitial Cystitis Symptom Index (ICSI) or Interstitial Cystitis Problem Index at 3 months. RESULTS: Twenty-two of 26 patients completed the 3-month follow-up; 18 completed the poststudy evaluation. The median symptom duration was 66 months (12-336). At 3 months, 31% (8/26) improved by global response assessment, 15% (4/26) had >50% improvement in the ICSI score, and 19% (5/26) had an improvement in the Interstitial Cystitis Problem Index score. Hunner lesions (HLs) predicted an improvement in the ICSI score (odds ratio = 15.4, 95% confidence interval: 1.7-224.6, P = .01), with 75% (3/4) of the responders having HL. Two patients withdrew because of hypertension or elevated serum glucose. The mean nuclear glomerular filtration rate declined at 3 months (98.9 ± 31.6 vs 84.2 ± 25.5 mL/min/1.73 m2, P = .01) and reversed to baseline after discontinuation of treatment. C2 levels did not correlate with symptoms but allowed dose reduction in 11 patients. CONCLUSION: Per American Urological Association guidelines, CyA can be effective in a proportion of patients with refractory IC-BPS. Patients with HL are more likely to benefit. Monitoring of C2 rather than trough levels can lead to dose reduction, thereby minimizing toxicity.
Authors: Jukka Sairanen; Teuvo L J Tammela; Mikael Leppilahti; Markku Multanen; Ilkka Paananen; Kari Lehtoranta; Mirja Ruutu Journal: J Urol Date: 2005-12 Impact factor: 7.450
Authors: Peter Jaksch; A Kocher; P Neuhauser; K Sarahrudi; J Seweryn; W Wisser; W Klepetko Journal: J Heart Lung Transplant Date: 2005-08 Impact factor: 10.247
Authors: G R Sant; K J Propert; P M Hanno; D Burks; D Culkin; A C Diokno; C Hardy; J R Landis; R Mayer; R Madigan; E M Messing; K Peters; T C Theoharides; J Warren; A J Wein; W Steers; J W Kusek; L M Nyberg Journal: J Urol Date: 2003-09 Impact factor: 7.450
Authors: Edward Cole; Nava Maham; Carl Cardella; Daniel Cattran; Stanley Fenton; Jayne Hamel; Catherine O'Grady; Robert Smith Journal: Transplantation Date: 2003-06-27 Impact factor: 4.939
Authors: Glenn T Werneburg; Karen S Keslar; Paige Gotwald; Johnathan Doolittle; Sarah C Vij; Byron H Lee; Daniel A Shoskes Journal: Transl Androl Urol Date: 2021-11